{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:20:40Z","timestamp":1792783240874,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T00:00:00Z","timestamp":1681257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T00:00:00Z","timestamp":1681257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Medical engineering cross research fund of Shanghai Jiaotong University","award":["YG2019ZDA11"],"award-info":[{"award-number":["YG2019ZDA11"]}],"id":[{"id":"https:\/\/ror.org\/0220qvk04","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970497"],"award-info":[{"award-number":["81970497"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170578"],"award-info":[{"award-number":["82170578"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s00535-023-01991-y","type":"journal-article","created":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T02:02:36Z","timestamp":1681264956000},"page":"633-641","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Minocycline vs. tetracycline in bismuth-containing quadruple therapy for Helicobacter pylori rescue treatment: a multicentre, randomized controlled trial"],"prefix":"10.1007","volume":"58","author":[{"given":"Yu","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinnan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuehua","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3127-6048","authenticated-orcid":false,"given":"Hong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,12]]},"reference":[{"key":"1991_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-327745","author":"P Malfertheiner","year":"2022","unstructured":"Malfertheiner P, Megraud F, Rokkas T, et al. Management of Helicobacter pylori infection: the Maastricht VI\/Florence consensus report. Gut. 2022. https:\/\/doi.org\/10.1136\/gutjnl-2022-327745.","journal-title":"Gut"},{"key":"1991_CR2","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1136\/gutjnl-2021-324032","volume":"70","author":"F Megraud","year":"2021","unstructured":"Megraud F, Bruyndonckx R, Coenen S, et al. Helicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community. Gut. 2021;70:1815\u201322.","journal-title":"Gut"},{"key":"1991_CR3","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S2468-1253(17)30219-4","volume":"2","author":"YT Kuo","year":"2017","unstructured":"Kuo YT, Liou JM, El-Omar EM, et al. Primary antibiotic resistance in Helicobacter pylori in the Asia-Pacific region: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017;2:707\u201315.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"24","key":"1991_CR4","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1097\/CM9.0000000000002546","volume":"135","author":"L Zhou","year":"2022","unstructured":"Zhou L, Lu H, Song Z, et al. 2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment. Chin Med J (Engl). 2022;135(24):2899\u2013910. https:\/\/doi.org\/10.1097\/CM9.0000000000002546","journal-title":"Chin Med J (Engl)"},{"key":"1991_CR5","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.gtc.2015.05.003","volume":"44","author":"DY Graham","year":"2015","unstructured":"Graham DY, Lee SY. How to effectively use bismuth quadruple therapy: the good, the bad, and the ugly. Gastroenterol Clin North Am. 2015;44:537\u201363.","journal-title":"Gastroenterol Clin North Am"},{"key":"1991_CR6","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/ajg.2016.443","volume":"111","author":"Q Chen","year":"2016","unstructured":"Chen Q, Zhang W, Fu Q, et al. Rescue therapy for Helicobacter pylori eradication: a randomized non-inferiority trial of amoxicillin or tetracycline in bismuth quadruple therapy. Am J Gastroenterol. 2016;111:1736\u201342.","journal-title":"Am J Gastroenterol"},{"key":"1991_CR7","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/hel.12313","volume":"21","author":"Z Song","year":"2016","unstructured":"Song Z, Suo B, Zhang L, et al. Rabeprazole, minocycline, amoxicillin, and bismuth as first-line and second-line regimens for Helicobacter pylori eradication. Helicobacter. 2016;21:462\u201370.","journal-title":"Helicobacter"},{"key":"1991_CR8","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/1751-2980.12334","volume":"17","author":"ZQ Song","year":"2016","unstructured":"Song ZQ, Zhou LY. Esomeprazole, minocycline, metronidazole and bismuth as first-line and second-line regimens for Helicobacter pylori eradication. J Dig Dis. 2016;17:260\u20137.","journal-title":"J Dig Dis"},{"key":"1991_CR9","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1128\/AAC.47.10.3138-3144.2003","volume":"47","author":"LM Best","year":"2003","unstructured":"Best LM, Haldane DJ, Keelan M, et al. Multilaboratory comparison of proficiencies in susceptibility testing of Helicobacter pylori and correlation between agar dilution and E test methods. Antimicrob Agents Chemother. 2003;47:3138\u201344.","journal-title":"Antimicrob Agents Chemother"},{"key":"1991_CR10","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. 2022;Version 12.0: http:\/\/www.eucast.org."},{"issue":"Suppl 3","key":"1991_CR11","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/j.1440-1746.2012.07069.x","volume":"27","author":"S Nakajima","year":"2012","unstructured":"Nakajima S, Inoue H, Inoue T, et al. Multiple-antibiotic-resistant Helicobacter pylori infection eradicated with a tailor-made quadruple therapy. J Gastroenterol Hepatol. 2012;27(Suppl 3):108\u201311.","journal-title":"J Gastroenterol Hepatol"},{"key":"1991_CR12","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/j.1440-1746.2006.04183.x","volume":"21","author":"K Murakami","year":"2006","unstructured":"Murakami K, Sato R, Okimoto T, et al. Effectiveness of minocycline-based triple therapy for eradication of Helicobacter pylori infection. J Gastroenterol Hepatol. 2006;21:262\u20137.","journal-title":"J Gastroenterol Hepatol"},{"key":"1991_CR13","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.cgh.2013.01.008","volume":"11","author":"X Liang","year":"2013","unstructured":"Liang X, Xu X, Zheng Q, et al. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. Clin Gastroenterol Hepatol. 2013;11:802-7.e1.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1991_CR14","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/S0140-6736(11)60020-2","volume":"377","author":"P Malfertheiner","year":"2011","unstructured":"Malfertheiner P, Bazzoli F, Delchier JC, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet. 2011;377:905\u201313.","journal-title":"Lancet"},{"key":"1991_CR15","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1136\/jcp.41.2.207","volume":"41","author":"CS Goodwin","year":"1988","unstructured":"Goodwin CS, Marshall BJ, Blincow ED, et al. Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies. J Clin Pathol. 1988;41:207\u201310.","journal-title":"J Clin Pathol"},{"key":"1991_CR16","doi-asserted-by":"publisher","first-page":"e0189888","DOI":"10.1371\/journal.pone.0189888","volume":"13","author":"Y Ji","year":"2018","unstructured":"Ji Y, Lu H. Meta-analysis: high-dose vs. low-dose metronidazole-containing therapies for Helicobacter pylori eradication treatment. PLoS ONE. 2018;13:e0189888.","journal-title":"PLoS ONE"},{"key":"1991_CR17","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1136\/gut.2009.192757","volume":"59","author":"DY Graham","year":"2010","unstructured":"Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010;59:1143\u201353.","journal-title":"Gut"},{"key":"1991_CR18","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/j.clinthera.2005.09.005","volume":"27","author":"K Smith","year":"2005","unstructured":"Smith K, Leyden JJ. Safety of doxycycline and minocycline: a systematic review. Clin Ther. 2005;27:1329\u201342.","journal-title":"Clin Ther"},{"key":"1991_CR19","first-page":"49","volume":"34","author":"M Barza","year":"1977","unstructured":"Barza M, Schiefe RT. Antimicrobial spectrum, pharmacology and therapeutic use of antibiotics. Part 1: tetracyclines. Am J Hosp Pharm. 1977;34:49\u201357.","journal-title":"Am J Hosp Pharm"},{"key":"1991_CR20","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1177\/1756283X09337342","volume":"2","author":"JP O'Connor","year":"2009","unstructured":"O\u2019Connor JP, Taneike I, O\u2019Morain C. Improving compliance with Helicobacter pylori eradication therapy: when and how? Therap Adv Gastroenterol. 2009;2:273\u20139.","journal-title":"Therap Adv Gastroenterol"},{"key":"1991_CR21","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/1751-2980.12271","volume":"16","author":"P Bai","year":"2015","unstructured":"Bai P, Zhou LY, Xiao XM, et al. Susceptibility of Helicobacter pylori to antibiotics in Chinese patients. J Dig Dis. 2015;16:464\u201370.","journal-title":"J Dig Dis"},{"key":"1991_CR22","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12839","volume":"26","author":"J Zhao","year":"2021","unstructured":"Zhao J, Zou Y, Li K, et al. Doxycycline and minocycline in Helicobacter pylori treatment: a systematic review and meta-analysis. Helicobacter. 2021;26: e12839.","journal-title":"Helicobacter"},{"key":"1991_CR23","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12722","volume":"25","author":"OP Nyssen","year":"2020","unstructured":"Nyssen OP, Perez-Aisa A, Rodrigo L, et al. Bismuth quadruple regimen with tetracycline or doxycycline versus three-in-one single capsule as third-line rescue therapy for Helicobacter pylori infection: Spanish data of the European Helicobacter pylori Registry (Hp-EuReg). Helicobacter. 2020;25: e12722.","journal-title":"Helicobacter"},{"key":"1991_CR24","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1007\/s10620-019-05694-4","volume":"64","author":"MA Alsamman","year":"2019","unstructured":"Alsamman MA, Vecchio EC, Shawwa K, et al. Retrospective analysis confirms tetracycline quadruple as best Helicobacter pylori regimen in the USA. Dig Dis Sci. 2019;64:2893\u20138.","journal-title":"Dig Dis Sci"},{"key":"1991_CR25","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ejim.2008.04.003","volume":"20","author":"M Akyildiz","year":"2009","unstructured":"Akyildiz M, Akay S, Musoglu A, et al. The efficacy of ranitidine bismuth citrate, amoxicillin and doxycycline or tetracycline regimens as a first line treatment for Helicobacter pylori eradication. Eur J Intern Med. 2009;20:53\u20137.","journal-title":"Eur J Intern Med"},{"key":"1991_CR26","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1046\/j.1083-4389.2002.00066.x","volume":"7","author":"F Perri","year":"2002","unstructured":"Perri F, Festa V, Merla A, et al. Amoxicillin\/tetracycline combinations are inadequate as alternative therapies for Helicobacter pylori infection. Helicobacter. 2002;7:99\u2013104.","journal-title":"Helicobacter"},{"key":"1991_CR27","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1046\/j.1523-5378.1999.99002.x","volume":"4","author":"G Realdi","year":"1999","unstructured":"Realdi G, Dore MP, Piana A, et al. Pretreatment antibiotic resistance in Helicobacter pylori infection: results of three randomized controlled studies. Helicobacter. 1999;4:106\u201312.","journal-title":"Helicobacter"},{"key":"1991_CR28","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3109\/00365529209000075","volume":"27","author":"TJ Borody","year":"1992","unstructured":"Borody TJ, George LL, Brandl S, et al. Helicobacter pylori eradication with doxycycline-metronidazole-bismuth subcitrate triple therapy. Scand J Gastroenterol. 1992;27:281\u20134.","journal-title":"Scand J Gastroenterol"},{"key":"1991_CR29","doi-asserted-by":"publisher","first-page":"367","DOI":"10.15403\/jgld.2014.1121.234.qrth","volume":"23","author":"E Ierardi","year":"2014","unstructured":"Ierardi E, Giangaspero A, Losurdo G, et al. Quadruple rescue therapy after first and second line failure for Helicobacter pylori treatment: comparison between two tetracycline-based regimens. J Gastrointestin Liver Dis. 2014;23:367\u201370.","journal-title":"J Gastrointestin Liver Dis"},{"key":"1991_CR30","first-page":"432","volume":"74","author":"Y Jin","year":"2019","unstructured":"Jin Y, Zhang S, Pan J, et al. Comparison of efficacy and safety of ilaprazole and esomeprazole both in initial treatment regimen and retreatment regimen of Helicobacter pylori infection in chronic gastritis. Pharmazie. 2019;74:432\u20138.","journal-title":"Pharmazie"},{"key":"1991_CR31","first-page":"1013","volume":"54","author":"L Zhang","year":"2015","unstructured":"Zhang L, Zhou L, Song Z, et al. Minocycline quadruple versus tailored therapy in retreatment of Helicobacter pylori infection. Zhonghua Nei Ke Za Zhi. 2015;54:1013\u20137.","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"1991_CR32","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1128\/AAC.8.4.453","volume":"8","author":"JA Jacobson","year":"1975","unstructured":"Jacobson JA, Daniel B. Vestibular reactions associated with minocycline. Antimicrob Agents Chemother. 1975;8:453\u20136.","journal-title":"Antimicrob Agents Chemother"},{"key":"1991_CR33","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/S0140-6736(74)90941-6","volume":"2","author":"DN Williams","year":"1974","unstructured":"Williams DN, Laughlin LW, Lee YH. Minocycline: Possible vestibular side-effects. Lancet. 1974;2:744\u20136.","journal-title":"Lancet"},{"key":"1991_CR34","doi-asserted-by":"publisher","first-page":"9251879","DOI":"10.1155\/2019\/9251879","volume":"2019","author":"L Zhang","year":"2019","unstructured":"Zhang L, Lan Y, Wang Q, et al. Application of minocycline-containing bismuth quadruple therapies as first-line regimens in the treatment of Helicobacter pylori. Gastroenterol Res Pract. 2019;2019:9251879.","journal-title":"Gastroenterol Res Pract"},{"key":"1991_CR35","first-page":"351","volume":"75","author":"AZ Ables","year":"2007","unstructured":"Ables AZ, Simon I, Melton ER. Update on Helicobacter pylori treatment. Am Fam Physician. 2007;75:351\u20138.","journal-title":"Am Fam Physician"},{"key":"1991_CR36","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-022-00953-7","author":"YM Ding","year":"2022","unstructured":"Ding YM, Li YY, Liu J, et al. The cure rate of 10-day bismuth-containing quadruple therapy for Helicobacter pylori eradication is equivalent to 14-day: a systematic review and meta-analysis. Clin Exp Med 2022. https:\/\/doi.org\/10.1007\/s10238-022-00953-7.","journal-title":"Clin Exp Med"},{"key":"1991_CR37","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/j.1365-2133.1996.tb06972.x","volume":"134","author":"V Goulden","year":"1996","unstructured":"Goulden V, Glass D, Cunliffe WJ. Safety of long-term high-dose minocycline in the treatment of acne. Br J Dermatol. 1996;134:693\u20135.","journal-title":"Br J Dermatol"},{"key":"1991_CR38","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1902\/jop.1992.63.1.13","volume":"63","author":"E Freeman","year":"1992","unstructured":"Freeman E, Ellen RP, Thompson G, et al. Gingival crevicular fluid concentration and side effects of minocycline: a comparison of two dose regimens. J Periodontol. 1992;63:13\u20138.","journal-title":"J Periodontol"},{"key":"1991_CR39","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1128\/AAC.12.5.642","volume":"12","author":"DW Gump","year":"1977","unstructured":"Gump DW, Ashikaga T, Fink TJ, et al. Side effects of minocycline: different dosage regimens. Antimicrob Agents Chemother. 1977;12:642\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1208\u201310","key":"1991_CR40","first-page":"1214","volume":"17","author":"SI Cullen","year":"1976","unstructured":"Cullen SI, Cohan RH. Minocycline therapy in acne vulgaris. Cutis. 1976;17(1208\u201310):1214.","journal-title":"Cutis"},{"key":"1991_CR41","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/j.1523-5378.1996.tb00003.x","volume":"1","author":"RW van der Hulst","year":"1996","unstructured":"van der Hulst RW, Keller JJ, Rauws EA, et al. Treatment of Helicobacter pylori infection: a review of the world literature. Helicobacter. 1996;1:6\u201319.","journal-title":"Helicobacter"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-023-01991-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00535-023-01991-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-023-01991-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T09:03:10Z","timestamp":1709110990000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00535-023-01991-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,12]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["1991"],"URL":"https:\/\/doi.org\/10.1007\/s00535-023-01991-y","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,12]]},"assertion":[{"value":"20 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Hong Lu has served as a paid speaker for CMS group, Hanhui-pharma, Headway, Abbott, AstraZeneca and Takeda. Other authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}